1. Market Research
  2. > Gastrointestinal Tract Cancer – Pipeline Review, H1 2013

Gastrointestinal Tract Cancer – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 699 pages

Gastrointestinal Tract Cancer – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Gastrointestinal Tract Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Tract Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Tract Cancer. Gastrointestinal Tract Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gastrointestinal Tract Cancer.
- A review of the Gastrointestinal Tract Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gastrointestinal Tract Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Tract Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Tract Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Gastrointestinal Tract Cancer - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
Introduction 14
Gastrointestinal Tract Cancer Overview 15
Therapeutics Development 16
Gastrointestinal Tract Cancer Therapeutics under Development by Companies 18
Gastrointestinal Tract Cancer Therapeutics under Investigation by Universities/Institutes 45
Late Stage Products 55
Mid Clinical Stage Products 56
Early Clinical Stage Products 57
Discovery and Pre-Clinical Stage Products 58
Gastrointestinal Tract Cancer Therapeutics - Products under Development by Companies 59
Gastrointestinal Tract Cancer Therapeutics - Products under Investigation by Universities/Institutes 106
Companies Involved in Gastrointestinal Tract Cancer Therapeutics Development 120
Gallbladder Cancer - Therapeutics Assessment 418
Drug Profiles 426
Gastrointestinal Tract Cancer Therapeutics - Drug Profile Updates 547
Gastrointestinal Tract Cancer Therapeutics - Discontinued Products 605
Gastrointestinal Tract Cancer Therapeutics - Dormant Products 617
Gallbladder Cancer - Product Development Milestones 677
Appendix 685

List of Tables

Number of Products Under Development for Gastrointestinal Tract Cancer, H1 2013 29
Products under Development for Gastrointestinal Tract Cancer - Comparative Analysis, H1 2013 30
Number of Products under Development by Companies, H1 2013 32
Number of Products under Development by Companies, H1 2013 (Contd..1) 33
Number of Products under Development by Companies, H1 2013 (Contd..2) 34
Number of Products under Development by Companies, H1 2013 (Contd..3) 35
Number of Products under Development by Companies, H1 2013 (Contd..4) 36
Number of Products under Development by Companies, H1 2013 (Contd..5) 37
Number of Products under Development by Companies, H1 2013 (Contd..6) 38
Number of Products under Development by Companies, H1 2013 (Contd..7) 39
Number of Products under Development by Companies, H1 2013 (Contd..8) 40
Number of Products under Development by Companies, H1 2013 (Contd..9) 41
Number of Products under Development by Companies, H1 2013 (Contd..10) 42
Number of Products under Development by Companies, H1 2013 (Contd..11) 43
Number of Products under Development by Companies, H1 2013 (Contd..12) 44
Number of Products under Development by Companies, H1 2013 (Contd..13) 45
Number of Products under Development by Companies, H1 2013 (Contd..14) 46
Number of Products under Development by Companies, H1 2013 (Contd..15) 47
Number of Products under Development by Companies, H1 2013 (Contd..16) 48
Number of Products under Development by Companies, H1 2013 (Contd..17) 49
Number of Products under Development by Companies, H1 2013 (Contd..18) 50
Number of Products under Development by Companies, H1 2013 (Contd..19) 51
Number of Products under Development by Companies, H1 2013 (Contd..20) 52
Number of Products under Development by Companies, H1 2013 (Contd..21) 53
Number of Products under Development by Companies, H1 2013 (Contd..22) 54
Number of Products under Development by Companies, H1 2013 (Contd..23) 55
Number of Products under Development by Companies, H1 2013 (Contd..24) 56
Number of Products under Development by Companies, H1 2013 (Contd..25) 57
Number of Products under Investigation by Universities/Institutes, H1 2013 59
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 60
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 61
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 62
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 63
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 64
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..6) 65
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..7) 66
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..8) 67
Comparative Analysis by Late Stage Development, H1 2013 68
Comparative Analysis by Mid Clinical Stage Development, H1 2013 69
Comparative Analysis by Early Clinical Stage Development, H1 2013 70
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 71
Products under Development by Companies, H1 2013 72
Products under Development by Companies, H1 2013 (Contd..1) 73
Products under Development by Companies, H1 2013 (Contd..2) 74
Products under Development by Companies, H1 2013 (Contd..3) 75
Products under Development by Companies, H1 2013 (Contd..4) 76
Products under Development by Companies, H1 2013 (Contd..5) 77
Products under Development by Companies, H1 2013 (Contd..6) 78
Products under Development by Companies, H1 2013 (Contd..7) 79
Products under Development by Companies, H1 2013 (Contd..8) 80
Products under Development by Companies, H1 2013 (Contd..9) 81
Products under Development by Companies, H1 2013 (Contd..10) 82
Products under Development by Companies, H1 2013 (Contd..11) 83
Products under Development by Companies, H1 2013 (Contd..12) 84
Products under Development by Companies, H1 2013 (Contd..13) 85
Products under Development by Companies, H1 2013 (Contd..14) 86
Products under Development by Companies, H1 2013 (Contd..15) 87
Products under Development by Companies, H1 2013 (Contd..16) 88
Products under Development by Companies, H1 2013 (Contd..17) 89
Products under Development by Companies, H1 2013 (Contd..18) 90
Products under Development by Companies, H1 2013 (Contd..19) 91
Products under Development by Companies, H1 2013 (Contd..20) 92
Products under Development by Companies, H1 2013 (Contd..21) 93
Products under Development by Companies, H1 2013 (Contd..22) 94
Products under Development by Companies, H1 2013 (Contd..23) 95
Products under Development by Companies, H1 2013 (Contd..24) 96
Products under Development by Companies, H1 2013 (Contd..25) 97
Products under Development by Companies, H1 2013 (Contd..26) 98
Products under Development by Companies, H1 2013 (Contd..27) 99
Products under Development by Companies, H1 2013 (Contd..28) 100
Products under Development by Companies, H1 2013 (Contd..29) 101
Products under Development by Companies, H1 2013 (Contd..30) 102
Products under Development by Companies, H1 2013 (Contd..31) 103
Products under Development by Companies, H1 2013 (Contd..32) 104
Products under Development by Companies, H1 2013 (Contd..33) 105
Products under Development by Companies, H1 2013 (Contd..34) 106
Products under Development by Companies, H1 2013 (Contd..35) 107
Products under Development by Companies, H1 2013 (Contd..36) 108
Products under Development by Companies, H1 2013 (Contd..37) 109
Products under Development by Companies, H1 2013 (Contd..38) 110
Products under Development by Companies, H1 2013 (Contd..39) 111
Products under Development by Companies, H1 2013 (Contd..40) 112
Products under Development by Companies, H1 2013 (Contd..41) 113
Products under Development by Companies, H1 2013 (Contd..42) 114
Products under Development by Companies, H1 2013 (Contd..43) 115
Products under Development by Companies, H1 2013 (Contd..44) 116
Products under Development by Companies, H1 2013 (Contd..45) 117
Products under Development by Companies, H1 2013 (Contd..46) 118
Products under Investigation by Universities/Institutes, H1 2013 119
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 120
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 121
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 122
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 123
Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 124
Products under Investigation by Universities/Institutes, H1 2013 (Contd..6) 125
Products under Investigation by Universities/Institutes, H1 2013 (Contd..7) 126
Products under Investigation by Universities/Institutes, H1 2013 (Contd..8) 127
Products under Investigation by Universities/Institutes, H1 2013 (Contd..9) 128
Products under Investigation by Universities/Institutes, H1 2013 (Contd..10) 129
Products under Investigation by Universities/Institutes, H1 2013 (Contd..11) 130
Products under Investigation by Universities/Institutes, H1 2013 (Contd..12) 131
Products under Investigation by Universities/Institutes, H1 2013 (Contd..13) 132
Bristol-Myers Squibb Company, H1 2013 133
Biocompatibles International plc, H1 2013 134
Boehringer Ingelheim GmbH, H1 2013 135
F. Hoffmann-La Roche Ltd., H1 2013 136
Kyowa Hakko Kirin Co., Ltd., H1 2013 137
Celsion Corporation, H1 2013 138
Biogen Idec Inc., H1 2013 139
Amgen Inc., H1 2013 140
Sanofi-Aventis, H1 2013 141
AstraZeneca PLC, H1 2013 142
Eli Lilly and Company, H1 2013 143
Viralytics Ltd., H1 2013 144
GlaxoSmithKline plc, H1 2013 145
Bioniche Life Sciences, Inc., H1 2013 146
Tekmira Pharmaceuticals Corp., H1 2013 147
Genentech, Inc., H1 2013 148
Inovio Biomedical Corporation, H1 2013 150
Watson Pharmaceuticals, Inc., H1 2013 151
Bavarian Nordic A/S, H1 2013 152
MedImmune LLC, H1 2013 153
Gilead Sciences, Inc., H1 2013 154
Biotest AG, H1 2013 155
GenVec, Inc., H1 2013 156
Daiichi Sankyo Company, Ltd, H1 2013 157
Merck and Co., Inc., H1 2013 158
AbGenomics International, Inc., H1 2013 159
Oxford BioMedica plc, H1 2013 160
Otsuka Pharmaceutical Co., Ltd., H1 2013 161
Bioneer Corporation, H1 2013 162
Infinity Pharmaceuticals, Inc., H1 2013 163
Takeda Pharmaceutical Company Limited, H1 2013 164
Delcath Systems, Inc., H1 2013 165
FibroGen, Inc., H1 2013 166
Light Sciences Oncology, Inc., H1 2013 167
MediGene AG, H1 2013 168
Celltrion, Inc., H1 2013 169
Nanotherapeutics, Inc., H1 2013 170
Prolexys Pharmaceuticals, Inc., H1 2013 171
Bio-Path Holdings, Inc., H1 2013 172
Histogen, Inc., H1 2013 173
ZIOPHARM Oncology, Inc., H1 2013 174
Novartis AG, H1 2013 176
Samyang Corporation, H1 2013 177
Geistlich Pharma AG, H1 2013 178
Aphios Corporation, H1 2013 179
ImClone Systems Incorporated, H1 2013 180
Astellas Pharma Inc., H1 2013 181
Chong Kun Dang Pharmaceutical, H1 2013 182
Eisai Co., Ltd., H1 2013 183
Gedeon Richter Plc., H1 2013 184
Kowa Company, Ltd., H1 2013 185
MDRNA, Inc., H1 2013 186
Nippon Kayaku Co., Ltd., H1 2013 187
Ono Pharmaceutical Co., Ltd., H1 2013 188
Pfizer Inc., H1 2013 189
SuperGen, Inc., H1 2013 190
Taiho Pharmaceutical Co., Ltd., H1 2013 191
Teva Pharmaceutical Industries Limited, H1 2013 192
Zeria Pharmaceutical Co Ltd, H1 2013 193
Cell Therapeutics, Inc., H1 2013 194
Enzon Pharmaceuticals, Inc., H1 2013 195

List of Figures

Number of Products under Development for Gastrointestinal Tract Cancer, H1 2013 29
Products under Development for Gastrointestinal Tract Cancer - Comparative Analysis, H1 2013 30
Products under Development by Companies, H1 2013 31
Products under Investigation by Universities/Institutes, H1 2013 58
Late Stage Products, H1 2013 68
Mid Clinical Stage Products, H1 2013 69
Early Clinical Stage Products, H1 2013 70
Discovery and Pre-Clinical Stage Products, H1 2013 71
Assessment by Monotherapy Products, H1 2013 431
Assessment by Combination Products, H1 2013 432
Assessment by Route of Administration, H1 2013 433
Assessment by Stage and Route of Administration, H1 2013 434
Assessment by Molecule Type, H1 2013 436
Assessment by Stage and Molecule Type, H1 2013 437

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.